Scientific evidence and controversies about pioglitazone and bladder cancer: Which lessons can be drawn?

Drug Safety

Volumn 36, Issue 9, 2013, Pages 693-707

  Faillie, Jean Luc ^a,b   Petit, Pierre ^a   Montastruc, Jean Louis ^c   Hillaire Buys, Dominique ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MURAGLITAZAR; PIOGLITAZONE; PLACEBO; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER RISK; CLINICAL TRIAL (TOPIC); DATA BASE; DRUG WITHDRAWAL; HEALTH; HEART FAILURE; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; SYSTEMATIC REVIEW; ANIMAL; CHEMICALLY INDUCED; EUROPE; PHARMACOEPIDEMIOLOGY; UNITED STATES; URINARY BLADDER NEOPLASMS;

ANIMALS; EUROPE; HUMANS; PHARMACOEPIDEMIOLOGY; RISK ASSESSMENT; THIAZOLIDINEDIONES; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 84887072282     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0086-y     Document Type: Review

References (71)

1. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106-18. (Pubitemid 39167514)
2. US Food and Drug Administration. Safety alerts for human medical products: Rezulin (troglitazone) (2000). http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm173081.htm. Accessed 14 Jun 2013.
3. European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim (2010). http://www.ema.europa.eu/ docs/en-GB/document-library/Press-release/2010/09/WC500096996.pdf. Accessed 14 Jun 2013.
4. US Food and Drug Administration. Approved drug products: Actos (pioglitazone hydrochloride) (1999). http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed 14 Jun 2013.
5. European Medicines Agency. European public assessment reports: product information for Actos (2013). http://www.emea.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000285/WC500021386.pdf. Accessed 14 Jun 2013.
6. European Medicines Agency. Assessment report for Actos, Glustin, Competact, Glubrava, Tandemact (2011). http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Assessment-Report-Variation/human/000285/WC500126656.pdf. Accessed 14 Jun 2013.
7. International Agency for Research on Cancer, World Health Organization. GLOBOCAN (2008). http://globocan.iarc.fr/. Accessed 14 Jun 2013.
8. ®) suspended (2011). http://www.ansm.sante.fr/var/ansm-site/storage/original/application/ 4e293bcd0814c025b94d46d7502a0958.pdf. Accessed 14 Jun 2013.
9. ®): increased incidence of bladder cancer [in German] (2011). http://www.bfarm.de/SharedDocs/1-Downloads/EN/vigilance/roteHandBriefe/ 2011/rhb-pioglitazon.pdf?-blob=publicationFile. Accessed 14 Jun 2013.
10. US Food and Drug Administration. Actos label information (1999). http://www.accessdata.fda.gov/drugsatfda-docs/label/1999/21073lbl.pdf. Accessed 14 Jun 2013.
11. El Hage J, Orloff D. Rodent carcinogenicity findings associated with PPAR agonists and their regulatory recommendations [abstract]. 3rd International Symposium on PPARS Efficacy and Safety; Monte Carlo; 2005. http://www. lorenzinifoundation.org/ppars2005/abstract-book.pdf. Accessed 30 Jun 2013.
12. Aoki T. Current status of carcinogenicity assessment of peroxisome proliferator-activated receptor agonists by the US FDA and a mode-of-action approach to the carcinogenic potential. J Toxicol Pathol. 2007;20(4):197-202.
13. Cohen SM. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci. 2005;87(2):322-7. (Pubitemid 41300679)
14. Dominick MA, White MR, Sanderson TP, et al. Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: evidence for urolithiasis as the inciting event in the mode of action. Toxicol Pathol. 2006;34(7):903-20. (Pubitemid 46011143)
15. Suzuki S, Arnold LL, Pennington KL, et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci. 2010;113(2):349-57.
16. Tseng CH, Tseng FH. Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2012;30(4):368-402.
17. Long GG, Reynolds VL, Lopez-Martinez A, et al. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event. Toxicol Pathol. 2008;36(2):218-31. (Pubitemid 351545780)
18. Sato K, Awasaki Y, Kandori H, et al. Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats. Toxicol Appl Pharmacol. 2011;251(3):234-44.
19. Chaffer CL, Thomas DM, Thompson EW, et al. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer. 2006;6:53. (Pubitemid 46277065)
20. Nakashiro KI, Hayashi Y, Kita A, et al. Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol. 2001;159(2):591-7. (Pubitemid 32751089)
21. Guan YF, Zhang YH, Breyer RM, et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia. 1999;1(4):330-9.
22. Yoshimura R, Matsuyama M, Segawa Y, et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003;104(5):597-602. (Pubitemid 36337259)
23. Kawakami S, Arai G, Hayashi T, et al. PPARgamma ligands suppress proliferation of human urothelial basal cells in vitro. J Cell Physiol. 2002;191(3):310-9. (Pubitemid 34462481)
24. Boiteux G, Lascombe I, Roche E, et al. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int J Cancer. 2009;124(8):1820-8.
25. Kassouf W, Chintharlapalli S, Abdelrahim M, et al. Inhibition of bladder tumor growth by 1,1-bis(3′-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res. 2006;66(1):412-8. (Pubitemid 43166049)
26. Chopra B, Georgopoulos NT, Nicholl A, et al. Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels. Cell Prolif. 2009;42(5):688-700.
27. Wei S, Yang J, Lee SL, et al. PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Lett. 2009;276(2):119-24.
28. Alzoubi K, Khabour O, Hussain N, et al. Evaluation of vitamin B12 effects on DNA damage induced by pioglitazone. Mutat Res. 2012;748(1-2):48-51.
29. Larsson SC, Orsini N, Brismar K, et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia. 2006;49(12):2819-23. (Pubitemid 44730282)
30. MacKenzie T, Zens MS, Ferrara A, et al. Diabetes and risk of bladder cancer: evidence from a case-control study in New England. Cancer. 2011;117(7):1552-6.
31. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674-85.
32. Lubet RA, Fischer SM, Steele VE, et al. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int J Cancer. 2008;123(10):2254-9.
33. La Maestra S, Micale RT, De Flora S, et al. DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents. Carcinogenesis. 2013;34(1):183-9.
34. Li H, Sorenson AL, Poczobutt J, et al. Activation of PPARgamma in myeloid cells promotes lung cancer progression and metastasis. PLoS One. 2011;6(12):e28133.
35. European Medicines Agency. Actos: product information as approved by the CHMP on 20 October 2011, pending endorsement by the European Commission (2011). http://www.ema.europa.eu/docs/en-GB/document-library/Other/2011/07/WC500109185. pdf. Accessed 14 Jun 2013.
36. Jaakkola T, Backman JT, Neuvonen M, et al. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol. 2006;61(1):70-8. (Pubitemid 43381239)
37. Conlon D. Goodbye glitazars? Br J Diabetes Vasc Dis. 2006;6(3):135-7. (Pubitemid 44056843)
38. Hillaire-Buys D, Faillie JL, Montastruc JL, et al. Stay vigilant: a glitazone (pioglitazone) can hide a glitazar! Eur J Clin Pharmacol. 2012;68(12):1681-3.
39. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-89. (Pubitemid 41416583)
40. Charbonnel B, Dormandy J, Erdmann E, et al. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care. 2004;27(7):1647-53. (Pubitemid 38857439)
41. PROactive Study Executive Committee and Data and Safety Monitoring Committee. PROactive study. Lancet. 2006;367(9515):982.
42. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180-8. (Pubitemid 47403104)
43. Mannucci E, Monami M, Lamanna C, et al. Pioglitazone and cardiovascular risk: a comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2008;10(12):1221-38.
44. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009;32(3):187-202.
45. Hillaire-Buys D, Faillie JL, Montastruc JL. Pioglitazone and bladder cancer. Lancet. 2011;378(9802):1543-4; author reply 1544-5.
46. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561-73. (Pubitemid 351482795)
47. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296(21):2572-81. (Pubitemid 44903861)
48. Piccinni C, Motola D, Marchesini G, et al. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011;34(6):1369-71.
49. Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. 2012;344:e3645.
50. Li W, Macdonald TM, Mackenzie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol. 2013;75(1):254-9.
51. Mamtani R, Haynes K, Bilker WB, et al. Long-term therapy with thiazolidinediones and the risk of bladder cancer: a cohort study [abstract]. J Clin Oncol. 2012;30 Suppl:Abstract 1503.
52. Zhu Z, Shen Z, Lu Y, et al. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2012;98(1):159-63.
53. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34(4):916-22.
54. Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55(7):1953-62.
55. Chang CH, Lin JW, Wu LC, et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology. 2012;55(5):1462-72.
56. Tseng CH. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care. 2012;35(2):278-80.
57. Colmers IN, Bowker SL, Majumdar SR, et al. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ. 2012;184(12):E675-83.
58. Kermode-Scott B. Meta-analysis confirms raised risk of bladder cancer from pioglitazone. BMJ. 2012;345:e4541.
59. Bosetti C, Rosato V, Buniato D, et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist. 2013;18(2):148-56.
60. Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med. 2013 [Epub ahead of print].
61. US Food and Drug Administration. Actos label information (2004). http://www.accessdata.fda.gov/drugsatfda-docs/label/2003/21073se8-020-actos-lbl. pdf. Accessed 14 Jun 2013.
62. US Food and Drug Administration. Actos medication guide (2009). http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/021073s037lbl.pdf. Accessed 14 Jun 2013.
63. US Food and Drug Administration. Drug safety communication: ongoing safety review of Actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure (2010). http://www.fda.gov/%20Drugs/DrugSafety/ ucm226214.htm. Accessed 14 Jun 2013.
64. European Medicines Agency. European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer (2011). http://www.ema.europa.eu/ema/index.jsp?curl=pages/ news-and-events/news/2011/07/news-detail-001311.jsp&mid=WC0b01ac058004d5c1. Accessed 14 Jun 2013.
65. European Medicines Agency. European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer: positive benefit-risk balance confirmed as second and third line treatment (2011). http://www.ema.europa.eu/ docs/en-GB/document-library/Press-release/2011/10/WC500116936.pdf. Accessed 14 Jun 2013.
66. US Food and Drug Administration. Actos label information (2011). http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/021073s043s044lbl.pdf. Accessed 14 Jun 2013.
67. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53. (Pubitemid 38579764)
68. IMS Health. Top US pharmaceutical products by spending (2012). http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/ Press%20Room/Top-Line%20Market%20Data%20&%20Trends/2011%20Top- line%20Market%20Data/Top-Products-by-Sales.pdf. Accessed 9 Jul 2012.
69. Montori VM, Fernandez-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med. 2009;150(11):803-8.
70. Oliveria SA, Koro CE, Yood MU, Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndr Clin Res Rev. 2008;2:47-57. (Pubitemid 351194192)
71. Lewis JD, Ferrara A, Peng T, et al. Cohort study of pioglitazone and bladder cancer in patients with diabetes: fourth interim analysis (8-year) report with data from January 1, 1997 to December 31, 2010 (2012). http://www.encepp.eu/encepp/openAttachment.htm;jsessionid= ac10290dd114e55b0b300e44bfeba88c399468fa486.rlmOahaInljyqA4IpR9BcxaNb3i?field= documents.otherDocument%5B0%5D&id=2903. Accessed 14 Jun 2013.